Clinical trial
Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic…
NCT00117429 · Marcus Altfeld, M.D., Ph.D., Other · Completed
Key facts
| NCT number | NCT00117429 |
|---|---|
| Title | Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART) |
| Official title | A Phase I, Randomized, Double-Blind Clinical Trial of the HIV gp120/NefTat/AS02A Vaccine Candidate in Subjects With Well-Controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART) |
| Lead sponsor | Marcus Altfeld, M.D., Ph.D., Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | HIV gp120/NefTat/AS02A Vaccine |
| Enrollment | 20 |
| Start date | Jun 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Jul 7, 2005 |
| Last update posted | Feb 15, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: